Prothena Corporation plc Ordinary Shares (PRTA)
PHARMACEUTICAL PREPARATIONS
Prothena Corporation plc Ordinary Shares (PRTA) is listed on Nasdaq, where it has traded since December 18, 2012.
- Listed On
- Nasdaq
- Listed Since
- December 18, 2012
- Employees
- 67
- Market Cap
- $451M
About Prothena Corporation plc Ordinary Shares
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 183 institutions reported holding PRTA, with 47.2 million shares worth $464.1 million in aggregate. The largest reported holder was FMR, with 7.2 million shares worth $70.5 million. Of the 5 largest holders listed below, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| FMR | 7,199,218 | $70M | Reduced 4.66% |
| Rubric Capital Management | 5,000,000 | $49M | Unchanged |
| BlackRock | 4,867,955 | $48M | Added 4.82% |
| Vanguard | 2,408,551 | $24M | Added 9.33% |
| State Street | 2,393,424 | $23M | Added 23.47% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is PRTA?
Prothena Corporation plc Ordinary Shares (PRTA) is listed on Nasdaq, where it has traded since December 18, 2012.
Who are the largest institutional holders of PRTA?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of PRTA were FMR, Rubric Capital Management and BlackRock.
How many institutions own PRTA?
183 institutions reported a position in PRTA for the quarter ended June 30, 2026, worth $464.1 million in total.
Did institutions buy or sell PRTA last quarter?
Of the 5 largest reported holders, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for PRTA.
Every reported institutional holder, plus insider and congressional trades in PRTA, on SentiSense.